NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations

NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology
Executive Brings Scientific and Business Experience in Global Operations

NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS),
announced today that Edward C. Geehr, M.D. has been named to the Company's
Board of Directors. Dr. Geehr brings extensive experience in developing and
operating global biotechnology businesses.

Serving as Executive Vice President of Operations, Dr. Geehr was responsible
for the global commercial operations of Abraxis Bioscience, a global
biotechnology company dedicated to the discovery, development and delivery of
next-generation therapeutics and core technologies that offer patients safer
and more effective treatment for cancer and other critical illnesses.

Previously Dr. Geehr served as President of Allez Spine, LLC, a developer,
manufacturer and distributor of medical devices, and was a co-founder and
executive chairman of IPC-The Hospitalist Company, which became a publicly
traded company in 2008. A graduate of Yale University, Dr. Geehr received his
Medical Degree from Duke University. He trained in Emergency Medicine at UCLA
and subsequently obtained Board certification. He is the author of many
scientific articles and books and held a faculty appointment at the University
of California, San Francisco School of Medicine.

Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are
extremely pleased that Dr. Geehr is joining our Board of Directors. His
experience in the growing fields of molecular science and treatments for
critical illnesses, combined with his leadership in developing and operating
global biotechnology businesses, will expand the scientific and practical
knowledge governing NeoStem's decision-making as we move into a new growth era
as a result of our acquisition last week of China Biopharmaceuticals Holdings,
Inc., which is anticipated to close before the end of this week."

Dr. Geehr stated, "I'm delighted to join the Board of Directors of NeoStem
Inc. This is an extraordinary, dynamic company led by thoughtful executives
and directors who have a strong knowledge base in science and technology as
well as in commercial business development. It will be a pleasure to work with
them to promote the growth of this rapidly expanding international company."

About NeoStem, Inc.
NeoStem is engaged in the business of developing stem cell therapies, pursuing
anti-aging initiatives and is developing a network of adult stem cell
collection centers that are focused on enabling people to donate and store
their own (autologous) stem cells when they are young and healthy for their
personal use in times of future medical need. The Company is also the licensor
of various stem cell technologies, including a worldwide exclusive license to
VSEL(TM) Technology which uses very small embryonic-like stem cells, shown to
have several physical characteristics that are generally found in embryonic
stem cells, and also is pursuing the licensing of other technologies for
therapeutic use. For more information, please visit: www.neostem.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could
cause future results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors" described
in the Company's Annual Report on Form 10-K for the fiscal year ended December
31, 2008 and the Company's other periodic filings with the Securities and
Exchange Commission. The Company's further development is highly dependent on
future medical and research developments and market acceptance, which is
outside its control.

CONTACT:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com

SOURCE NeoStem, Inc.

NeoStem, Inc., Robin Smith, Chief Executive Officer, +1-212-584-4180,
rsmith@neostem.com